Here's My Top Space Stock to Buy Right Now, And Why It's Better Than SpaceX

Rocket Lab highlights a $2.4B launch backlog and 90 total Electron/Neutron missions worth $2.36B, anchored by at least seven Neutron-specific commercial launches through 2029 and a $397M U.S. Space Force contract. In Q2, Rocket Lab grew revenue 62% to $234M with losses narrowing to $0.08/share, while capex was tightly controlled at $26M (down from $32M). The article contrasts this with SpaceX’s 554% capex surge to $18.3B (nearly $16B into its Colossus AI data center), framing Rocket Lab as the lower-spend, higher-upside bet ahead of Neutron’s push toward the launchpad by end-2026.

Analysis

The market is likely to misread this as a simple “lower-spend good / higher-spend bad” comparison. The real mechanism is that RKLB is approaching a credibility inflection: if Neutron reaches even a modest launch cadence, the stock can migrate from a development multiple to a backlog-conversion multiple, which matters more than near-term revenue growth. The biggest near-term winner is likely RKLB’s valuation, not its P&L; the biggest loser is any competitor trading on the assumption that launch share is permanently locked.

The consensus may be overestimating how much SpaceX’s AI capex changes RKLB’s competitive position. That spending can compress SpaceX’s private-market optics, but it does not automatically improve RKLB’s win rate unless Neutron proves reliability and schedule discipline. The more important second-order effect is on defense and national-security launch demand: if RKLB becomes a credible second source, it can win budget share from incumbents over 6-18 months, but only after successful milestone execution.

The main risk is timing. In the next 1-3 months, this trades on launch-pad progress, contract announcements, and any slip in test readiness; in 6-12 months it trades on whether launch insurance, payload integration, and refurbishment economics actually support a repeatable gross margin model. A failed test or another meaningful delay would likely unwind the multiple quickly because the backlog is still conditional, not cash-revenue. The thesis is falsified if Neutron slips materially past the stated timeline or if contract backlog stops converting into executed launches.

Key Decisions for Investors

• Long RKLB tactically into Neutron milestone headlines; treat it as a 1-3 month catalyst trade, not a long-duration core position. Risk/reward is attractive only if schedule confidence improves; trim if management starts talking about planning for launch rather than launch execution.
• Use RKLB as a relative-value long only against aerospace/defense names that are not launch-levered; avoid comparing it to SpaceX economics as if they were directly substitutable. If RKLB cannot demonstrate cadence, the premium should compress back toward a pure development-story multiple.
• Watch for confirmation from backlog conversion and launch-readiness metrics, not headline contract counts. If the next update shows no slip and no capex blowout, add on weakness; if capex rises sharply without an execution step-up, fade rallies.
• No direct short is compelling from the supplied universe; the cleaner expression is a modest long RKLB with a hard stop on schedule slippage or test failure. The thesis is invalidated if Neutron’s first meaningful launch window moves materially beyond management’s current target.